Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Applied Digital Corporation (APLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Applied Digital Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Applied Digital Corporation trades at $30.92 (market cap $8.78B). The key difference: Applied Digital Corporation is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Applied Digital Corporation nearer its low. Which is the better fit depends on your goals.
| ACAD | APLD | |
|---|---|---|
Market Cap | $4.49B | $8.78B |
Sector | Health | Technology |
52-Week High | $28.06 | $49.65 |
52-Week Low | $20.06 | $9.18 |
Enterprise Value | $3.69B | $9.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Applied Digital (APLD) trades at $33.50, up 1.33% with a bearish technical signal despite bullish oscillators. The company shows rapid revenue growth but significant losses, with a -58.38% net margin and negative cash flow from operations. Recent developments include major AI data center expansions and $36 billion in contracted backlog, though profitability remains elusive amid heavy capital spending.
Outlook remains speculative with strong analyst support (100% buy ratings, $71.43 target) but substantial execution risks. The stock offers high-growth AI infrastructure exposure but faces customer concentration, mounting debt, and uncertain path to profitability. Current valuation at 27x sales appears rich given negative earnings and cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →
